In the frontal cortex of AD patients and APP/PS1 transgenic mice, SLC30A10 levels are consistently lower, indicating that its dysregulation may be a contributing factor to the AD onset and progression (Bosomworth et al., 2013). Here, SLC30A10 is linked to Alzheimer disease.